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Abstract
Iron deficiency anemia is considered the most common and widespread nutritional form 
of anemia in childhood. Red cells are hypochromic and microcytic with low mean cor-
puscular volume (MCV), low mean corpuscular hemoglobin (MCH) and low reticulocyte 
hemoglobin content (CHr). Red blood cell distribution width (RDW) is increased. Serum 
iron is reduced, transferrin is increased and serum ferritin is decreased. Prematurity, 
decreased dietary source, malabsorption and blood loss represent the most common 
causes of iron deficiency. Recommended oral dose of elemental iron is 2–6 mg/kg/day; 
when normal hemoglobin values are reached, treatment must be generally continued for 
3 months in order to replenish iron stores. Rarely intravenous therapy is required. The 
pediatricians and other health care providers should strive to prevent and eliminate iron 
deficiency and iron-deficiency anemia.
Keywords: iron deficiency, anemia, children, hypochromic microcytic anemia, 
prevention
1. Introduction
In children, iron represents an essential nutrient for growth and proper function of many 
organs and systems, mainly erythropoiesis. It must be obtained from the diet and absorbed in 
the upper gastrointestinal tract. When iron requirements are not met, as when the balance of 
iron intake, iron stores and the body’s loss are insufficient to fully support the production of 
erythrocytes, it is referred to as iron deficiency (ID). In 30% of cases, the ID, if left untreated, 
evolves in iron deficiency anemia (IDA) which represents the most frequent form of anemia 
in childhood.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Epidemiology
ID and IDA are among the most widespread morbid conditions in the world and represent 
a public health problem both in developed and developing countries. All reports agree that 
IDA is the most common anemia worldwide in school-age children. A recent WHO report, 
obtained from 200 countries, showed a significant reduction in prevalence of ID/IDA that rose 
from 40.2% in 1990 to 32.9% in 2010. In countries with limited resources, ID affects about two-
thirds of children and adolescents; it is estimated that around 25% of preschool children suf-
fers from IDA. In Africa, the prevalence of IDA among school-age children still ranges from 
64.3 to 71%. In Europe, the overall prevalence of ID/IDA is 2–4%, with two peaks between the 
first and third year of life (2.3–15%) and adolescence (3.5–13% in males, 11–33% in females). 
ID/IDA is less than 5% in Northern and Western Europe, but it is considerably higher in 
Eastern Europe (9–50%). In the United States, IDA prevalence is 1.6–7.4% among pediatric 
population; in children 1–5 years old, the prevalence of ID is 7–8% and about one-third of 
them have IDA. The prevalence is higher among children 1–2 years old (13.5 and 2.7%, respec-
tively). Although the prevalence of IDA has decreased over the past decade, data from many 
surveys indicate that it remains relatively high among low-income family; the prevalence of 
ID/IDA was 17% in 1–2 years old and 6% in 3–4 years old among Mexican American toddlers, 
and 12% in 1–2 years old and 5% in 3–4 years old in other low-income family [1–7].
3. Pathophysiology
The amount of iron contained in the body, in relation to the various ages, is summarized in Table 1. 
During the first year of life, total-body iron increases by 240 mg; nearly 80% of that iron is used for 
expanded hemoglobin production (50%) and iron stores (30%). Over this age, iron intake or stores 
must remain sufficient for the ongoing growth and increased red cell mass. Iron metabolism is 
essentially a “closed system” in which almost all metal from the hemocateresis (about 95%) is con-
tinuously recycled to meet the demands of the various compartments, especially the production of 
new red blood cells (RBC). Only a small part of the body iron is represented by that absorbed from 
the diet. In adults, less than 5% of the iron requirement for the erythropoiesis is obtained from food 
while in the child the iron destined for hemoglobin synthesis derives for 30% from the diet; the 
remainder part come from the deposits and the rework of the iron released by the hemocateresis. 
From the sixth month, the total body iron progressively increases (70%) to answer to the high rate 
Newborn (3.300 kg) Children (35 kg) Adult (75 kg)
Total content 240–250 mg 1.5–2 g 2.5 (f)–4 (m) g
Hemoglobin 132–137.5 mg (55%) 1–1.4 g (68%) 2.00–2.72 g (50–70%)
Ferritin and hemosiderin (deposit) 101–105 mg (42%) 400–500 mg (27%) 0.81–1.08 g (15–30%)
Myoglobin 60–80 mg (4%) 120–300 mg (3–5%)
Enzymes 7–7.5 mg (3%) 9.12 mg (0.6%) 18–24 mg (0.2–5%)
Table 1. Iron content in the body in newborn, child and adult.
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of growth and the expansion of the erythrocyte mass. As more than 60% of the iron absorbed is 
destined to this function (1 kg of weight corresponds to 75 ml of blood or 9 g of hemoglobin and 
30 mg of iron). It is clear that in this age, iron balance is more precarious, and possible dietary 
imbalances could reduce tolerance limits (delayed weaning, vegetarian diet and malabsorption).
Physiological losses are minimal (about 0.5–1 mg/day) and are mostly due to exfoliation of 
the mucous membranes (bile, intestine, kidneys and lungs) and of the skin. Since there are 
no specific mechanisms of iron excretion through the liver or kidneys, iron balance is mainly 
controlled at the intestinal level by modulating its absorption. A balanced diet of an adult 
contains about 10–15 mg of iron. The absorption of iron in the foods, which varies from 5 to 
15% (up to 20% for the meal), compensates the physiological losses. In case of blood losses 
(menstruation or other bleeding), acute or chronic hemolytic events, or periods of increased 
demand, such as rapid growth, pregnancy and competitive sports activity, intestinal absorp-
tion can increase up to four times.
Regarding the developmental age, the iron requirement (LARN 2014) to be taken with the diet, 
after 6 months is about 7–11 mg/day which corresponds to about 0.8–1 mg of iron absorbed. 
Of these, around 75% are used for growth and 25% to offset the losses. In adolescent age, after 
the appearance of the menarche (considering that with each menstrual cycle are lost about 
10–25 mg of iron), the amount to be taken with the diet rises to 13–18 mg/day [6–15].
4. Etiology
The causes of iron deficiency are numerous, but in the children, these are basically due to four 
causes: decreased reserves at birth, inadequate intake with the diet, reduced intestinal absorp-
tion or chronic losses of blood. Table 2 examines all causes [1–4]. “Physiological anemia” 
Decreased reserves at birth: prematurity and/or twinning, intrauterine fetus-fetal and fetus-maternal transfusions, 
exanguino-transfusion at birth or severe IDA in the mother, early clamping of the umbilical cord.
Inadequate intake: late weaning, incongruous diet (uncontrolled vegetarian-vegan) and/or increased needs: rapid 
weight-growth such as low birth weight, prematurity, adolescent development and cyanotic heart disease.
Reduced absorption: celiac disease, intestinal bowel disease, Hirschsprung disease, large intestinal resections (short 
bowel), use of antacids and proton pump inhibitors, excess in the diet of phytates (soy and cereals), bran, starch, 
calcium, polyphenols (tea and coffee), soy protein, casein and egg white, Helicobacter pylori infection, giardiasis and other 
intestinal parasites, obesity, bariatric surgery, immune deficiencies with mucosal atrophy, intestinal lymphangiectasia.
Blood loss: abundant and/or frequent menstruation, intolerance of cow's milk protein, consumption more than 
500 ml/day of cow-milk, Meckel's diverticulum, esophageal varices, polyps and hemorrhoids, intestinal bowel 
disease, intestinal parasitosis, epistaxis, severe hematuria, prolonged use of aspirin, cortisones, nonsteroidal anti-
inflammatory drugs, frequent blood sampling for diagnostic purposes (in the newborn, especially if immature, and 
in the small infant).
Hereditary forms (rare diseases): DMT1 deficiency, transferrin deficiency, refractory iron deficiency anemia (IRIDA).
Chronic pulmonary diseases: pulmonary hemosiderosis, cystic fibrosis, bronchopulmonary dysplasia.
Iron deficiency anemia associated with anemia of chronic diseases.
Table 2. Main causes of iron deficiency in childhood and adolescence.
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develops in the postnatal period, and iron stores are sufficient to provide erythropoiesis in 
the first 6 months of life if there is no significant blood loss. In low birth weight infants and in 
babies with perinatal blood loss, the stores are exhausted earlier. The amount of iron in breast 
milk is at the highest level in the first month, but it decreases gradually in the subsequent 
periods and is reduced up to 0.3 mg/l approximately in the fifth month. Although the amount 
of iron received from breast milk is typically low, its absorption is considerably high (50%). 
Solid foods, given after the sixth month, should be rich especially in iron, zinc, phosphorus, 
magnesium, calcium and vitamin B6. According to the WHO data, 98% of the iron require-
ment in infants aged 6–23 months should be introduced by solid foods. In patients, especially 
in older children and adolescents, blood losses should be considered, if inadequate intake can 
be excluded or there is inadequate response to iron treatment.
5. Clinical presentation
Mild iron deficiency, without anemia, mostly occurs asymptomatic or can only occur with poor 
exercise tolerance and/or asthenia. With the worsening of iron deficiency, asthenia becomes 
more relevant, especially in relation to the reduced amount of myoglobin and enzymes for the 
oxidative phosphorylation. When anemia appears, the most significant symptom is pallor of 
the mucous membranes and of the skin. In about 10% of children with IDA, there is modest 
splenomegaly as a result of mild hemolysis. The reduction in hemoglobin is slow. The child is 
Figure 1. Manifestation and multisystem sequelae of iron deficiency.
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able to compensate poor tissue oxygenation without significant clinical manifestations except 
for a modest tachycardia, with an increase in cardiac output and a moderate tachypnea. This 
mechanism is due to an increase of 2,3-diphosphoglycerate (2-3-DPG) in red blood cells, that 
induces a displacement to the right of the dissociation curve of the hemoglobin, allows a 
greater release of oxygen to the tissues.
Whereas iron plays a fundamental role in numerous metabolic processes in different 
organs and tissues, its deficiency is not only reflected on erythropoiesis but can also have 
consequences at various levels. The preschooler children may show lack of appetite, lack 
of desire to play and sometimes irritability; the older child can have asthenia, listlessness, 
headache and reduced school performance. Recent literature highlights the association 
between chronic iron deficiency and possible compromise of the central nervous system, 
with intellectual, attention, memory, learning, fine motor skills and verbal fluency defi-
cits. Some studies have shown an association between iron deficiency and increased risk 
of developing stroke, idiopathic intracranial hypertension, cranial nerve paralysis, sleep 
disorders, febrile seizures and attention deficit and hyperactivity disorder (ADHD). Iron 
deficiency and chronic anemia can cause glossitis, angular cheilitis, dysphagia, reduction 
of gastric acidity, nail dystrophy, hair fragility, amenorrhea, slowing of growth and greater 
susceptibility to infections. In severe forms (hardly observable in our social context), we can 
observe pica (ingestion of nonnutritive substances) and/or geophagy (ingestion of earth or 
mud) [1–4, 7, 8, 14–20] (Figure 1).
6. Laboratory findings
Table 3 shows the normal values of the erythrocyte parameters in relation to age. In IDA 
hemoglobin, red blood cells and hematocrit are below two standard deviation (SD) respect 
normal value according to the age, gender and race. Typically, peripheral blood smear shows 
hypochromic (pale) and microcytic erythrocytes with variable size and shape (anisopoikilo-
cytosis). Subtle change in morphologic features may be observed before than overt anemia 
occurs, as manifestation of iron-deficient erythropoiesis. Change of red cell distribution, 
evaluated by red cell distribution width (RDW) and hemoglobin distribution (HDS) usu-
ally are present before overt microcytosis (reduction of MCV) and hypochromia (reduction 
of MCH and MCHC) are observed. The values of the iron system parameters (serum iron, 
transferrin, total iron binding capacity and ferritin) undergo variations due to age and are 
summarized in Table 4. In ID/IDA, serum iron is reduced (less than 50 μg/dl), and serum 
transferrin is increased. Transferrin saturation index below 16% is considered very sensitive 
for IDA. Measurement of serum ferritin is currently the laboratory test recommended for 
diagnosing iron deficiency. In the absence of an associated disease, a low value is an early and 
highly specific indicator of ID. The WHO criteria proposed to define depleted iron storages 
are 12 μg/l for children under 5 years and 15 μg/l for those over 5 years. However, because 
ferritin is an acute-phase reactive protein, it may be elevated by infection, acute and chronic 
inflammatory disorders, malignant disease, liver disease and starvation. In particular, in case 
of infection or inflammation the cut-off for serum ferritin for diagnosis of IDA is elevated 
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to 30–50 μg/l. Combining the evaluation of the levels of c-reactive protein (CRP) is required 
to rule out an inflammation. In children, serum soluble transferrin receptor (sTfR) has been 
reported to be a sensitive indicator of iron deficiency and is appeared to be relatively less 
influenced by inflammation than ferritin. Unfortunately, reference values of these parameters 
in children are not available and not all laboratories may perform it. So far, in routine practice, 
evaluation of sTfR is not needed for a diagnosis of IDA. Reticulocyte hemoglobin (CHr) is 
another parameter useful for the diagnosis of ID. Values less than 27.5 pg are considered very 
sensitive and specific for IDA (83 and 72%, respectively). Measurement of red blood cell pro-
toporphyrin IX and zinc protoporphyrin (ZPP), that are increased in IDA, provides another 
parameter that may help in the diagnosis. The combination of red blood cell parameters with 
serum ferritin and transferrin saturation index still remains the common approach to investi-
gate anemia for the diagnosis of IDA. Serum hepcidin is a promising novel biomarker for the 
diagnosis of iron disorders. It is decreased in ID, and its levels may become undetectable in 
severe cases of IDA. As this marker is influenced by inflammation, renal and liver function, 
these conditions should be assessed. In the future, when commercial test for measurement 
of urinary or serum hepcidin will be available, these parameters might be useful in differ-
ential diagnosis. Thrombocytosis (platelets count between 500,000 and 700,000 mcL) occurs 
frequently. In severe forms of IDA may be present a low grade of hemolysis due to the rigidity 
Age Hb (g/dl) Ht (%) GR (102/l) MCV (fl) MCH (pg) MCHC (g/dl)
Mean −2SD Mean −2SD Mean −2SD Mean −2SD Mean −2SD Mean −2SD
Bird 16.5 13.5 51 42 4.7 3.9 108 98 34 31 33 30
1–3 days 18.5 14.5 56 45 5.3 4.0 108 95 34 31 33 29
1 week 17.5 13.5 54 42 5.1 3.9 107 88 34 28 33 28
2 weeks 16.5 12.5 51 39 4.9 3.6 105 86 34 28 33 28
1 month 14.0 10.0 43 31 4.2 3.0 104 85 34 28 33 29
2 months 11.5 9.0 35 28 3.8 2.7 96 77 30 26 33 29
3–6 months 11.5 9.5 35 29 3.8 3.1 91 74 30 25 33 30
0.5–2 years 12.0 10.5 36 33 4.5 3.7 78 70 27 23 33 30
2–6 years 12.5 11.5 37 34 4.6 3.9 81 75 27 24 34 31
6–12 years 13.5 11.5 40 35 4.6 4.0 86 77 29 25 34 31
2–18 years
Female 14.0 12.0 41 36 4.6 4.1 90 78 30 25 34 31
Male 14.5 13.0 43 37 4.9 4.5 88 78 30 25 34 31
Adults
Female 14.0 12.0 41 36 4.6 4.0 90 80 30 26 34 31
Male 15.5 13.5 47 41 5.2 4.5 90 80 30 26 34 31
Table 3. Normal erythrocyte parameters in developmental age.
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of red cell membrane, than mild increase of hemolysis markers may be observed. Bone mar-
row examination is no longer performed in the work-up for IDA for assessing iron stores. 
However, as diagnosis of iron deficiency is somewhat complex, the use of several combined 
indicators seems to provide the best assessment of iron status.
Age Male Female
Ferritin ng/ml ng/ml
1–30 days 6–400 6–515
1–6 days 6–410 6–340
7–12 months 6–80 6–45
1–5 years 6–24 6–24
6–9 years 10–55 10–55
10–14 years 23–70 6–40
14–19 years 23–70 6–40
Serum iron μg/dl μg/dl
1–5 years 22–136 22–136
6–9 years 39–136 39–136
10–14 years 28–134 45–145
14–19 years 34–162 28–184
TIBC μg/dl μg/dl
1–5 years 268–441 268–441
6–9 years 240–508 240–508
10–14 years 302–508 318–575
14–19 years 290–570 302–564
Transferrin mg/dl mg/dl
1–30 days 97–205 92–208
1–6 months 106–325 128–309
7–12 months 178–357 145–364
1–3 years 196–365 149–382
4–6 years 202–350 174–399
7–9 years 149–353 186–368
10–12 years 173–380 185–377
13–15 years 171–374 193–391
16–18 years 194–348 181–416
Table 4. Values of serum ferritin, serum iron, total iron binding capacity (TIBC) and transferrin in pediatric age (ranging 
from 2.5 to 97.5 percentiles).
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Iron deficiency develops in three steps. The first one is iron depletion or prelatent stage. Iron 
stores are lowered or absent (serum ferritin is reduced below normal cut-off) while other 
parameters are unchanged. In this stage, erythropoiesis is still normal. The second stage is 
defined as latent stage or deficiency. Iron supply for erythropoiesis became reduced; serum 
iron transferrin saturation are reduced as well as CHr; StfRs increases. The third stage overt 
IDA is characterized by a progressive impairment of erythropoiesis and modifications of 
hematological parameters [1–4, 8, 9, 20–32].
At the end of this process appears the hypochromic microcytic anemia characterized by:
Parameters Iron deficiency anemia Hetherozygous 
thalassimia
Anemia of chronic diseases
MCV Reduced Reduced Normal
MCH Reduced Reduced Reduced
MCHC Reduced Normal Reduced
RDW Increased Normal Normal
Ferritin Reduced Normal or increased Reduced-normal-increased
Serum iron Reduced Normal Reduced
Transferrin Increased Normal Reduced
Serum transferrin receptor Increased Increased Normal
Tranferrin saturation index Reduced Normale or increased Normal
Others Response to iron 
treatment
HBA2 concentration No response to iron treatment
Table 5. Differential diagnosis of microcytic anemia.
• Reduction of Hb, RBC number and hematocrit
• Reduction of MCV, MCH and MCHC
• Hypochromic cells with a tendency to microcytosis
• Increase of RDW > 15%
• Reduction of CHr <27.5 pg
• Reduction of serum iron <30 mg/dl; increase of total serum transferrin o of TIBC, >350 mg/dl; reduction of IS 
<16%; reduction of serum ferritin <10–12 ng/ml
• Increase of sTfR a 10–14 mg/l
• Reduction of reticulocyte (inconstant)
• Increase of zinc protoporphyrin > 60–80 μmol/mol-heme*
• Increase of free erythrocyte protoporphyrin (FEP) > 10 mg/dl*
• Increase of platelets count (inconstant) between 600,000–1000,000 mcL
• Rarely modest hemolysis
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In the diagnostic evaluation of IDA, a correct differential diagnosis must always be made 
with the other forms of microcytic-hypochromic anemia, such as thalassemia and anemia of 
chronic diseases (Table 5).
7. Treatment
Despite ID/IDA are well-known medical issues, this topic is not noticed adequately, and the 
literature contains only few publications related to iron treatment recommendations; this 
resulting in part from the lack of contemporary scientific literature regarding evidence-based 
treatment of IDA. The therapeutic approach of ID/IDA is widely variable and often subop-
timal as often pediatricians administer inadequate daily doses of iron or inappropriate iron 
salt formulations or too short iron replacement [38]. The principles of ID/IDA management 
are based on some cornerstones: confirm the diagnosis, recognition and whenever possible, 
management of the underlying cause(s), provide adequate iron therapy, either orally or par-
enterally, and finally confirm the success of the treatment (correction of the hemoglobin levels 
and finally replenishment of body iron storage). If diet intake is inadequate, the first step is 
correction of the nutritional iron intake. In cases of ID or of IDA with good levels of hemoglo-
bin, this approach may be sufficient to correct iron depletion. Usually, dietary counseling and 
oral iron therapy are combined.
Limited high-quality evidence supports the management of iron deficiency anemia. Oral iron 
replacement is preferred primarily because it is economical and has few side effects. Oral iron 
supplement is the treatment of choice by selecting the most appropriate compound, whereas 
parenteral route of administration is recommended only for selected patients. Iron-containing 
oral preparations currently available in the market are innumerous, with a variety of pharma-
ceutical forms including liquid preparations as guts, elixir, syrups, pills and effervescent tablets. 
Unfortunately, oral iron formulations are known to be far from ideal, mainly because of absorption 
and tolerability; also the palatability of the liquid preparation is often a real problem for children. 
Stain of teeth may occur if not thoroughly cleaned. Their chemistry is also heterogeneous, includ-
ing either divalent (Fe2+, or ferrous) or trivalent (Fe3+, or ferric) iron, in form of iron salts or their 
complex-forming substrate iron. Treatment must correct hemoglobin levels and then gradually 
replenish iron stores. The time required varies from 3 to 6 months after the anemia is relieved. If 
the treatment is not continued, relapse is common. What really matter in different oral iron prepa-
rations is the content of elemental iron absorption. As a general rule, oral iron preparations do 
not contain more than 30% of elemental iron, but a source of confusion is represented by the fact 
that such proportion can vary by manufacturer, as well as in different countries. Ferrous formula-
tions are recommended by international literature, scientific societies and international agencies 
as the preparations that are more effective. Ferric iron is poorly and ineffectively absorbed. The 
ferrous sulfate was first introduced by the French physician Pierre Blaud in the last half of 1800 
and still remains the mainstay of treatment for adults as reasonable well absorbed, effective and 
inexpensive. Unfortunately, the tolerability of this salt is poor, making it unacceptable for many 
patients. Therefore, many other effective ferrous salts have been offered as ferrous gluconate, 
ferrous ascorbate, ferrous lactate, ferrous succinate, ferrous fumarate and ferrous glycine sulfate. 
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No one compound seems better than the others. Recent studies showed that ferrous bisglycinate 
chelate and ferrous bisglycinate chelate plus alginic acid have a good absorption at reduced doses 
(25–40%) in comparison with ferrous sulfate and an optimal tolerance. Unfortunately iron for-
mulations, especially in older children and adolescent, may induce gastrointestinal discomfort 
mainly represented by including metallic taste, vomiting, heartburn, epigastric and abdominal 
pain, nausea, flatulence, dyspepsia, constipation and diarrhea. Likely due to the oxidative prop-
erties of iron on the gastrointestinal mucosa, these problems occur frequently, especially when 
iron is taken fasting. The stool often may turn black, which is not harmful, and treatment does 
not have to be interrupted. When side effects occur, iron can be taken with meals. Alternatively, 
smaller doses could be taken between meals. Ascorbic acid may improve the bioavailability of 
iron salts, but it increases the frequency of side effects. As the treatment is long, a good compli-
ance is required for the success of the therapy. For this reason, the best tolerated preparation and 
schedule must be tailored for each patient in order to encourage compliance.
Standard dose is 2–6 mg/kg/day in terms of elemental iron, in 2–3 divided doses up to a maxi-
mum of 150–200 mg daily. It may be recommended to start treatment with low dose increasing 
day by day to full doses during 7–10 days. However, the optimum frequency of daily doses 
is uncertain. Single dose daily is well tolerated and effective when compared to divided dose, 
especially in children less than 2 years. Administration on empty stomach before sleeping 
seems to be more effective as decreased gastrointestinal motility of sleep enhance absorption. 
The absorptive capacity of iron in the duodenum is near complete saturated with about 25 mg 
of iron. It is conceivable that the treatment on 25 mg/day saturates the intestinal absorption 
capacity so that the next day doses are much less absorbed. It is interesting that in children 
with gastrointestinal side effects, iron administration once every other day or twice a week 
might be more effective than daily doses and might reduce gastrointestinal discomfort.
When patients do not tolerate full doses, a less iron dose may be administrated, but in this 
case, it is necessary to treat longer.
As gastrointestinal discomforts are more frequent when the stomach is empty, patients prefer 
to take iron immediately after or even with meal. Also, if it is clear that in this way the absorp-
tion is reduced to 30%, the better compliance to iron treatment may be preferred than a better 
absorbent. However, it is important to inform the patients that in this case some foods may 
influence iron absorption: orange juice, meat, poultry and fish enhance absorption while food 
high in phytates, phosphates or tannates (e.g., cereals, beans, soys, tea and milk) reduce it. The 
ensuing reduction of adherence, in combination with the need of prolonged treatment, results 
in undertreatment significant proportion of IDA patients in daily clinical practice. There has 
been an increasing awareness of a previously overlooked potentially negative effect of oral 
iron, that is, the change in gut microbiome. In the absence of ongoing blood loss or intestinal 
malabsorption response to iron treatment is rapid. So far, within 24 h, the child feels bet-
ter, shows less irritability and an increased appetite. A peak of reticulocytes may observe at 
5–7 days but routinely this re-evaluation is not performed in children to avoid discomfort. 
The hemoglobin measured after a month of treatment shows an increase of 1–2 g/dl. Since 
IDA has been treated and hemoglobin concentrations are healthy, full blood count and mark-
ers of iron status should be measured during the subsequent 6–12 months.
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Treatment failure is common due to poor medication adherence, adverse effects related to 
excessive dosing and lack of evidence-based management guidelines. If after a month of 
treatment the anemia, in otherwise healthy individual, does not respond, the causes of the 
iron deficiency anemia must be carefully reevaluated. It is important to analyze the duration 
of therapy, ongoing blood loss, high gastric pH due to assumption of antacid, histamine-2 
blocker, gastric acid pump inhibitor, deficit of Vitamin B12, folic acid, zinc, or hypothyroidism, 
a coexistent disease that interferes with iron absorption (chronic inflammation and inflamma-
tory bowel disease or neoplasia). Finally, an incorrect diagnosis of the microcytic anemia, as 
thalassemia, sideroblastic anemia or genetic IRIDA as well as patients with elevated hepcidin 
levels driven by inflammation, must be ruled out. Unfortunately, many patients are often lost 
to follow-up [1–3, 22–24].
Considering the risk of adverse reaction, parenteral iron therapy should be reserved for 
selected patients with severe gastrointestinal absorption disorders including inflammatory 
bowel disease or short bowel syndrome, or when a rapid replacement of iron is required 
or an absolute intolerance to oral administration is demonstrated. There not indications of 
parenteral iron treatment for pediatric patients with celiac disease in gluten-free diet as they 
can absorb oral iron salt preparations with good clinical results. Of interest the observation 
that ferrous bisglycinate chelate is well absorbed also in patients with overt celiac disease 
(personal data-in press Minerva Pediatrica 2018).
The benefits of new generation parenteral formulations are greater than their risks, if 
adequate measures are taken to ensure the early detection and effective management of 
allergic reactions. Iron preparations should only be given in a protected environment, where 
resuscitation facilities are available in order to treat immediately. The practice of first giving 
the patient a small test dose is not a reliable way to predict how the patient will respond 
when the full dose is given. A test dose is therefore no longer recommended but instead 
caution is warranted with every dose of intravenous iron that is given, even if previous 
administrations have been well tolerated. Various iron formulations for intravenous use are 
now available but the approval of the products may differ in different countries. The first 
parenteral iron formulation was a high molecular weight iron dextran. However, intramus-
cular injection of iron dextran is discouraged because it is painful, produce long-standing 
skin discoloration, and it may be a potential risk of developing a rhabdomyosarcoma or 
fibrosarcoma. Intravenous administration is no longer available due to its relatively high 
incidence of hypersensitivity reactions. Low-molecular weight iron dextran, introduced in 
the 1990s is less likely to cause such reactions but the use in now is limited as formulations 
with improved safety profile have been licensed. Fe-gluconate (Ferlixit®) is less dangerous 
but is containing benzilic acid that may cause seizure in infant less than 3 years. Fe-sucrose 
(Venofer®) is much more expensive but represents today the best product for children con-
sidering the low risk if reacted. Finally, new and promising preparations are now under 
investigation but at the moment they are not approved for pediatrics: Fe-carboxymaltose 
(Ferrinject®), Fe-isomaltoside (Monofer®) and Ferumoxytol (Ferraheme®). Severe hyper-
sensitivity reactions with these preparations are exceptional. Simple recommendations to 
minimize the risk include slow administration with careful patient monitoring during and 
after treatment, an adequate clinical environment with trained staff and the avoidance of 
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antihistamine premedication. Iron sucrose and sodium ferric gluconate are approved for 
both adults and children, but typically require multiple doses to achieve adequate iron 
replacement. For the ferric carboxymaltose, the recommended infusion time is only 15 min 
and is administrated once a week. It is approved in Europe and in the US for adults, not yet 
approved for pediatrics.
Red cell transfusion should be reserved to severe anemia, less than 5 g/dl of hemoglobin, 
requiring rapid correction as in children with cardiac dysfunction.
The total amount of parenteral iron to be administered may be calculated according to the 
following formula:
  Weight  (kg) × volemia  (80 ml / kg) ×  3.4 ∗ × g  (normal Hb for age − patient Hb) ×  1.5 ∗∗ 
  ∗ 1 g of Hb alloy 3.4 mg of iron,   ∗∗ correction to replenish stocks 
The total dose should be divided into several administrations (initially every 2–3 days then 
every 1–2 weeks) to be given in a slow infusion (recommended in 1–4 h, the single dose should 
not exceed 5 mg/kg) [1–4, 31–40].
8. Prevention
In preterm infants (born at less than 37 weeks’ gestation) the prevention of ID/IDA with the 
administration of iron is well-established practice, even if there is no clear evidence of benefits 
on long-term outcomes such as growth and neurobehavioral development. Infants who are 
exclusively breastfed should receive 1–3 mg/kg/day of elemental iron supplementation from 
1–12 months of age, except for those who have had multiple blood transfusions; 1 mg/kg/
day supplementation if using iron-fortified formula. For healthy full-term infants exclusively 
breastfed infants, the AAP recommends 1 mg/kg/day of iron supplementation at 4 months of 
age until appropriate iron-containing foods are introduced. WHO recommended daily iron 
supplementation with 60 mg of elemental iron to prevent iron deficiency in menstruating 
adolescent girls where the prevalence of anemia is about 20%.
According to the American Academy of Pediatrics, the prevention of iron deficiency is an 
important issue of public health and the universal screening, between 12 and 18 months, is 
useful to assess the possible risk factors [41–45].
9. Conclusion
Prevention and early diagnosis of ID and IDA in childhood are important to ensure normal 
growth and performance and to avoid possible damage on neurocognitive and behavioral 
development. Diagnostics are generally relatively easy and are based on the evaluation of a 
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few simple hematological and biochemical parameters. Treatment may have some difficulty 
regarding patient’s compliance. So important is the role of the pediatrician in approaching 
the problem of iron deficiency in every phase of the intervention, from prevention, diagnosis 
and treatment.
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